Home
Clinical Resources Search
PQI: Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

Download PQI pdf 0.27MB

Last Updated: March 14, 2023

By: Kayla Boyd, PharmD, BCOP

About this PQI

This PQI is centered on erythropoietin stimulating agent (ESA) ineligibility in patients with myelodysplastic syndromes (MDS), as well as understanding when an MDS patient fails ESA treatment or has a suboptimal ESA response.

More About This PQI

PQI in Action Articles:

Erythropoietin_Myelodysplastic_syndromes pdf 2.1MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Myelodysplastic Syndrome (MDS) Myeloproliferative Neoplasm ERYTHROPOIETIN STIMULATING AGENT (ESA) Luspatercept Reblozyl

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI: Imetelstat (RYTELO®) in the treatment of low-to-intermediate-1-risk myelodysplastic syndromes (MDS)

PQI in Action: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI in Action: Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

PQI in Action: Ropeginterferon alfa-2b-njft (BESREMi®) Use in Polycythemia Vera

PQI in Action: Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

PQI in Action: Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

PQI in Action: Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings